OSAKA, Japan — (BUSINESS WIRE) — Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (「Takeda」) today announced the results of a phase 3 trial investigating the efficacy and safety of …
Takeda Data at ISTH 2021 Highlight the Benefits of Prophylaxis for Patients with Rare Bleeding Disorders
OSAKA, Japan — (BUSINESS WIRE) — Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (「Takeda」) today announced the results of a phase 3 trial investigating the efficacy and safety of …